Antibody developability intelligence

Map antibody liabilities from sequence.

BioFold reads VH and VL sequences, maps developability liabilities to their molecular drivers, and returns a versioned profile with CDR localization, residue-level trace, warnings, and request provenance.

Inside every analysis

Sequence-native analysis
CDR-aware liability map
Hydrophobicity and charge
Chemical motif screening
Residue-level provenance
Versioned API output

Explore the product report View the API See the evidence

Liability profile: library BF-024 BioFold 1.0

Ranked candidate BF-021

H3W100localized

L3localized

Primary liability driver: H3 W100. Modeled quantity: relative H3/L3 hydrophobic profile.

Library: 24 candidates
Selection budget: 8 candidates
CDR localization: 23 candidates
Whole-chain continuation: 1 candidate
Analysis: Sequence-derived liability profile
Version: BioFold 1.0
Applicability: Paired VH/VL antibody sequences
Comparator: Library-relative liability rank
Quantity status: Sequence liability index
Provenance: Engine version and input hash

CDR-aware map Residue-level trace Versioned result

Developability evidence

Measured against established antibody assays.

BioFold sequence descriptors track hydrophobic interaction, self-association, viscosity, and immunoassay readouts across the Jain 2017 clinical-stage antibody panel.

Hydrophobic interaction

HIC | n=137 | Spearman ρ=0.410

The CDR3 hydrophobic quantity carries the strongest HIC association in the full API cohort. The raw nonpolar-carbon comparator reaches ρ=0.371 on the same panel.

Self-association

SMAC | n=137 | Spearman ρ=0.390

The whole-sequence hydrophobic quantity tracks SMAC across the same clinical-stage antibody panel and stays linked to its engine version and cohort record.

Charge-linked panel

Six assays | Versioned associations

Net charge associates with AC-SINS at ρ=0.329, CSI-BLI at 0.303, PSR at 0.378, BVP at 0.267, CIC at 0.308, and ELISA at 0.287.

CDR localization

134 of 137 conserved-anchor records

Conserved CDR3 anchors localize liability drivers to H3 and L3. Whole-chain continuation preserves a complete sequence profile across all 137 records.

Each association retains its cohort, assay, statistic, expected direction, result field, comparator, and engine version.

Method

From sequence features to a traceable liability profile.

Every result separates model-derived molecular quantities, empirical assay context, and the decision rule selected by the team.

Molecular map

Where does the liability originate?

BioFold maps hydrophobicity, formal charge, chemical motifs, responsible residues, localization, and sequence-level contributions.

Assay context

Which experimental signal provides context?

The response links each empirical association to its cohort, assay, statistic, direction, comparator, and result field.

Decision layer

How does the team use the profile?

Budget, protected positions, assay priorities, rank criteria, comparator, and tie-break rules are visible in the report.

Antibody API

Sequence in. Liability map out.

Send a VH sequence and an optional VL sequence. BioFold returns versioned developability quantities, CDR localization, warnings, the scientific result, and request provenance.

Primary input: vh
Paired input: vl
Analysis: CDR-aware liability mapping with whole-chain continuation
Output: Versioned quantities, residue trace, warnings, and provenance

Request API access

POST /v1/antibody Versioned antibody contract

Request example

Sequences abbreviated for display

{
  "vh": "EVQLVESGGGLVQ...VTVSS",
  "vl": "DIQMTQSPSSLSA...LEIK"
}

Response metadata excerpt

Versioned capability metadata

{
  "capability": "antibody",
  "payload": {
    "method": "predict_antibody_developability",
    "quantity_status": {
      "hydrophobic_proxy": ["PROXY", "PHYSICAL-ESTIMATE"],
      "formal_charge_descriptor": ["DERIVED"],
      "chemical_motif_convention": ["CONVENTIONAL"],
      "empirical_liability_references": ["EMPIRICAL"]
    },
    "estimate_kind": "antibody_developability_liabilities",
    "validation_metrics": {
      "cohort": "Jain 2017 clinical-stage antibody panel",
      "n": 137,
      "statistic": "spearman_rho",
      "associations": [
        {"assay": "HIC", "result_field": "cdr3_hydrophobic", "value": 0.410},
        {"assay": "SMAC", "result_field": "hydrophobic_total", "value": 0.390},
        {"assay": "PSR", "result_field": "net_charge", "value": 0.378}
      ]
    },
    "comparator": {
      "assay": "HIC",
      "baseline": {"quantity": "raw_nonpolar_carbon_count", "value": 0.371},
      "current_api": {"result_field": "cdr3_hydrophobic", "value": 0.410}
    },
    "min_tier": "Pro"
  }
}

Every response also carries: request ID, engine version, input hash, served time, watermark, warnings, and the scientific result.

Versioned response Residue trace in the result payload

Product workflow

One engine, two decision moments.

BioFold turns sequence sets into prioritized liability maps before synthesis and parent-variant comparisons after assay.

Before synthesis

Rank the library before the bench.

Supply paired VH and VL sequences, the synthesis budget, assay priorities, and protected positions. BioFold ranks the library and retains the molecular driver behind every candidate position.

Triage output

Fixed-budget candidate ranking, liability drivers, CDR localization, and residue-level provenance.

Product report API contract

After assay

Compare the parent and variant.

Add the assay result and proposed substitution. BioFold calculates the modeled sequence delta, checks protected positions, and surfaces the liability changes associated with the edit.

Optimization output

Parent-variant delta, protection checks, chemical-liability screen, and prioritized sequence designs.

Optimization view Method trace

Product report

Every decision keeps its molecular trace.

Switch between library triage and parent-variant optimization while preserving the source sequence, comparator, quantity status, engine version, and responsible residues.

The report is built for review, export, and handoff across computational, developability, and program teams.

Source class: Versioned candidate analysis
Version: BioFold 1.0
Applicability: Paired VH/VL antibody libraries
Comparator: Library-relative liability rank
Quantity status: Sequence-derived liability profile
Provenance: Engine version and input hash
Decision rule: Fixed synthesis budget
Audit trail: Residue-level drivers retained

Candidates24

Synthesis budget8

CDR localized23

Selected8

Rank	Candidate	Localization	Relative H3/L3 profile	Selection state
01	BF-021	H3/L3 localized	Lower	Selected
09	BF-018	H3/L3 localized	Moderate	Reserve

BF-021

Rank: 01
Localization: H3/L3
Relative profile: Lower
Selection state: Selected

BF-018

Rank: 09
Localization: H3/L3
Relative profile: Moderate
Selection state: Reserve

Library rank combines H3/L3 hydrophobicity, whole-sequence hydrophobicity, charge, chemical motifs, localization, and residue-level trace.

BioFold access

Bring a library. Leave with a liability map.

Start with paired VH and VL sequences, assay priorities, protected positions, and the synthesis or optimization decision your team needs to make.

BioFold returns versioned liability profiles, candidate ranks, parent-variant deltas, residue-level drivers, and an exportable audit trail.

Request access Explore the product report